Vertex, Alios BioPharma commence studies for Hepatitis C treatment
Vertex Pharmaceuticals and Alios BioPharma, together have initiated two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, inhibitors of the hepatitis C NS5B polymerase.
ALS-2200 and ALS-2158 are pan-genotypic nucleotide analogues, designed to inhibit the replication of the hepatitis C virus by acting on the NS5B polymerase.
The two Phase 1 studies will be randomized, double-blind, placebo-controlled studies, with the primary goals of evaluating the safety and tolerability of single ascending doses of ALS-2200 and ALS-2158 in healthy volunteers and of multiple ascending doses in people with chronic genotype-1 hepatitis C.
A secondary objective will be to evaluate the effects on viral kinetics of ALS-2200 and ALS-2158 during seven days of dosing in people with hepatitis C.
Vertex holds worldwide development and commercialization rights for ALS-2200 and ALS-2158, which were discovered by Alios BioPharma.
The company is likely to present the data in the second quarter of 2012, which is expected to initiate studies to evaluate multiple all-oral, interferon-free combination regimens for chronic hepatitis C.
Related Insight
Suppliers Directory
Sonic Clinical Trials - Dedicated Central Laboratory
Sonic Clinical Trials is a dedicated central laboratory service providing comprehensive clinical trials support to the pharmaceutical and biotechnology industries.
Contract Research & Services > Contract Research > Suppliers
ADVANCELL - Advanced Nanomedicine for Treatment of Unmet Medical Needs
ADVANCELL is an emerging Spanish biotechnology focused on the development of promising drug candidates with significant commercial potential in oncology, dermatology and neurology indications. We create these new product opportunities by leveraging our innovative nanosystems technology and by in-licensing promising projects at a pre-clinical stage. In both cases, we are open to approaches from parties interested in collaboration. ADVANCELL has currently several programs in clinical development and pursues a series of preclinical opportunities, both proprietary and in collaboration. The Company headquarters are located in the Barcelona Science Park (PCB), Barcelona, and its nanosystems laboratory is in Santiago de Compostela, Spain.
Contract Research & Services > Contract Research > Suppliers
Hudson Robotics - Lab Automation Solutions.
We produce robots that allow users to easily turn microplate readers into automated screening systems. We have microplate movement and storage systems, as well as liquid handling solutions. We also offer complete workcells for biological research and drug discovery, in which our products are integrated with third party equipment to solve complex laboratory protocols.
Contract Research & Services > Contract Research > Suppliers
Medical Research Network - Clinical Trial Support Organisation
The Medical Research Network (MRN) is a unique clinical trial support organisation (CTSO). The MRN has been involved in the conduct of over 50 clinical trials across a wide range of therapeutic areas, in particular oncology and rheumatology.
Contract Research & Services > Contract Research > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Contract Research Intelligence
Efficacy and Surgical Research Services (ESRS)
Published by Toxikon Europe
Contract Research & Services > Contract Research > White Papers
Pharmacovigilance Services
Published by DOKUMEDS
Contract Research & Services > Contract Research > White Papers
Bioceros Brochure: Therapeutic Monoclonal Antibodies
Published by Bioceros
Contract Research & Services > Contract Research > White Papers
Big Pharma R&D – thinking big, acting small
Published by Kinapse
Contract Research & Services > Contract Research > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.